Herbert Irving Comprehensive Cancer Center   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3
Founded: New York City NY United States (1911)

Organization Overview

First Clinical Trial
1996
NCT00002723
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Herbert Irving Comprehensive Cancer Center

Active Ingredients

Drugs in Phase 3 Trials (30)

aldesleukin (proleukin) (2 trials)

alendronic acid (fosamax) (1 trial)

autologous bone marrow (4 trials)

bleomycin (blenoxane) (2 trials)

calcium carbonate (1 trial)

calcium citrate (1 trial)

carboplatin (paraplatin) (7 trials)

cyclophosphamide (cytoxan) (10 trials)

cyclosporine (sandimmune) (3 trials)

cytarabine (cytosar-u) (2 trials)

dexrazoxane (zinecard) (1 trial)

docetaxel (taxotere) (6 trials)

doxorubicin (Doxil) (6 trials)

estramustine (emcyt) (4 trials)

etoposide (vepesid) (9 trials)

ibandronate (boniva) (2 trials)

icosapent ethyl (vascepa) (1 trial)

interferon gamma-1b (actimmune) (3 trials)

mitoxantrone (novantrone) (2 trials)

naltrexone (revia) (2 trials)

peripheral blood hematopoietic cell (10 trials)

prednisone (meticorten) (4 trials)

risedronate (actonel) (1 trial)

sargramostim (leukine) (16 trials)

suramin (1 trial)

thiotepa (5 trials)

urea (1 trial)

vincristine (oncovin) (3 trials)

vitamin d3 (1 trial)

zoledronic acid (zometa) (4 trials)

Drugs in Phase 2 Trials (46)

allogeneic hematopoietic stem cells (Hemacord) (1 trial)

alvac-cea-b7.1 vaccine (1 trial)

anastrozole (arimidex) (1 trial)

Anti-thymocyte Globulin (Rabbit) (Thymoglobulin) (1 trial)

autologous mononuclear stem cell (1 trial)

bone marrow cells (1 trial)

bortezomib (velcade) (1 trial)

busulfan (myleran) (3 trials)

carmustine (bicnu) (1 trial)

celecoxib (celebrex) (1 trial)

cisplatin (platinol) (3 trials)

cp4071 (1 trial)

dacarbazine (dtic-dome) (1 trial)

fludarabine (fludara) (1 trial)

fluorouracil (efudex) (2 trials)

flutamide (eulexin) (1 trial)

gefitinib (iressa) (1 trial)

gemcitabine (gemzar) (4 trials)

idarubicin (idamycin) (1 trial)

ifosfamide (ifex) (3 trials)

interferon alpha-2b (Intron-A) (2 trials)

irinotecan (Camptosar) (2 trials)

leucovorin (1 trial)

leuprolide (lupron) (1 trial)

l-glutamine (1 trial)

melphalan (alkeran) (5 trials)

methylprednisolone (medrol) (1 trial)

mitomycin (mutamycin) (1 trial)

mycophenolate (myfortic) (1 trial)

octreotide (sandostatin) (1 trial)

paclitaxel (taxol) (3 trials)

palbociclib (ibrance) (1 trial)

pertuzumab (perjeta) (1 trial)

procarbazine (matulane) (1 trial)

romidepsin (istodax) (1 trial)

silymarin (1 trial)

tazarotene (tazorac) (2 trials)

temozolomide (temodar) (3 trials)

temsirolimus (torisel) (1 trial)

tetanus toxoid (1 trial)

thalidomide (Thalomid) (2 trials)

topotecan (hycamtin) (3 trials)

trastuzumab (herceptin) (1 trial)

vatalanib (1 trial)

vinblastine (velban) (1 trial)

vinorelbine (navelbine) (1 trial)

Drugs in Phase 1 Trials (7)

bevacizumab (avastin) (1 trial)

mage-10.a2 (1 trial)

mart-1 antigen (1 trial)

ny-eso-1 (2 trials)

thrombopoietin (1 trial)

tyrosinase peptide (1 trial)

vaccinia-tricom vaccine (1 trial)

Drugs in Other Trials (4)

clodronate disodium (1 trial)

demeclocycline hydrochloride (declomycin) (1 trial)

pancrelipase (creon) (1 trial)

tetracycline (tetrex) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Amyloidosis (Phase 2)

Arthralgia (Phase 3)

Astrocytoma (Phase 2)

Basal Cell Nevus Syndrome (Phase 2)

Breast Diseases (Phase 2)

Breast Neoplasms (Phase 3)

Carcinoma (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Carcinoma, Transitional Cell (Phase 2)

Cardiotoxicity (Phase 3)

Central Nervous System Neoplasms (Phase 2)

Colorectal Neoplasms (Phase 2)

Drug-Related Side Effects and Adverse Reactions (Phase 2)

Endometrial Neoplasms (Phase 2)

Ependymoma (Phase 2)

Fallopian Tube Neoplasms (Phase 2)

Glioma (Phase 2)

Hodgkin Disease (Phase 3)

Hypercalcemia (Phase 3)

Immunoglobulin Light-chain Amyloidosis (Phase 2)

Kidney Neoplasms (Phase 2)

Leiomyosarcoma (Phase 2)

Leukemia (Phase 3)

Leukemia, Lymphoid (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)

Leukemia, Myeloid (Phase 2)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 3)

Melanoma (Phase 1)

Mesothelioma (Phase 2)

Multiple Myeloma (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 3)

Neoplasms, Plasma Cell (Phase 2)

Nervous System Neoplasms (Phase 2)

Neuroblastoma (Phase 1)

Neuroectodermal Tumors (Phase 2)

Neuroectodermal Tumors, Primitive (Phase 2)

Neurotoxicity Syndromes (Phase 2)

Oligodendroglioma (Phase 2)

Osteoporosis (Phase 3)

Ovarian Neoplasms (Phase 2)

Peripheral Nervous System Diseases (Phase 2)

Plasmacytoma (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Preleukemia (Phase 2)

Prostatic Neoplasms (Phase 3)

Sarcoma (Phase 2)

Skin Neoplasms (Phase 2)

Syndrome (Phase 2)

Tetanus (Phase 2)

Ureteral Neoplasms (Phase 2)

Urethral Neoplasms (Phase 2)

Urinary Bladder Neoplasms (Phase 2)

Uterine Cervical Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 54
  • # of Trial APIs: 87